Biogen Other — Total Revenue increased by 0.2% to $55.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 88.4%, from $29.40M to $55.40M. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests successful monetization of secondary assets or emerging business lines, while a decrease may indicate the sunsetting of legacy products or a shift in strategic focus.
This metric represents the aggregate gross revenue generated by products or services that do not fall into the company's...
Peers often report this as 'Other Revenue' or 'All Other' segments, which typically represent a small percentage of total corporate revenue.
biib_segment_other_total_revenue| Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $3.40M | $2.00M | $15.20M | $17.60M | $24.10M | $29.40M | $46.80M | $55.30M | $55.40M |
| QoQ Change | — | -41.2% | +660.0% | +15.8% | +36.9% | +22.0% | +59.2% | +18.2% | +0.2% |
| YoY Change | — | — | — | +417.6% | >999% | +93.4% | +165.9% | +129.5% | +88.4% |